aap reports strong Q4/2014 sales growth in trauma

annual sales reach EUR 31.7 million driven by a 63% sales growth in LOQTEQ®

Berlin, (PresseBox) - aap Implantate AG (XETRA: AAQ.DE) generated, according to preliminary figures, sales of EUR 8.6 million in the fourth quarter of 2014. In full year 2014 the company reported sales of EUR 31.7 million thereby achieving a result within the target range of EUR 30 million to EUR 34 million communicated in October 2014. Of these EUR 31.7 million an amount of EUR 30.7 million is attributable to the continued operations (aap Implantate AG excluding EMCM B.V.). As a result of the sale of EMCM B.V. on February 28, 2014, the sales figures for the financial year 2014 include sales from EMCM for January and February totaling EUR 1.0 million.

The positive sales development was particularly driven by the trauma business. This underlines the strategic alignment of the management board transforming aap Implantate AG in a leading European trauma company. Sales in the trauma business increased in the fourth quarter of 2014 compared to the corresponding period in the last year by 25% to EUR 3.9 million (Q4/2013: EUR 3.1 million). In full year 2014 the company reported sales of EUR 12.3 million in the trauma business, corresponding to a growth rate of 27% with respect to the result in the previous year (FY 2013: EUR 9.6 million).

Considering the sales in the trauma business more detailed, the development of the LOQTEQ® product family has to be emphasized particularly. Here the company was able to increase sales in the fourth quarter of 2014 over the corresponding period in the previous year (Q4/2014: EUR 1.9 million) by 56% to EUR 3.0 million. In full year 2014 aap Implantate AG realized a significant sales growth of 63% with LOQTEQ® as well reaching a result of EUR 8.2 million (FY 2013: EUR 5.0 million). The positive sales development of LOQTEQ® demonstrates that the IP protected product family is increasingly well established at the market and has a strong appeal among several customers. All in all the growth dynamic in the fourth quarter of 2014 and in the full year 2014 underlines the successful implementation of the strategy sustainably aligning aap Implantate AG on the trauma business.

In its biomaterials business aap Implantate AG reported a sales growth of 10% to EUR 16.4 million (FY 2013: EUR 15.0 million) in financial year 2014 compared to the previous year. The decline in the fourth quarter of 2014 to EUR 3.7 million results from extensive initial deliveries in the corresponding quarter of the previous year.

Furthermore the company still holds intensive talks with selected strategic investors and private equity investors on a possible transaction for aap Biomaterials GmbH (bone cements and mixing systems and biomaterials). The objective is still to conclude a definitive agreement in the first quarter of 2015 and thereby to transform aap Implantate AG into a company that is solely active in the trauma business.

The preliminary results contained in this press release are unaudited and based on management's initial analysis of operations for the periods ended December 31, 2014, and are therefore subject to change. aap Implantate AG plans to announce its final, audited results of the financial year 2014 on March 31, 2015.

We will give a first forecast for the financial year 2015 and the first quarter of 2015 as well as the evaluation of the management agenda 2014 within a separate release at the beginning of February 2015.

Press releases you might also be interested in

Subscribe for news

The subscribtion service of the PresseBox informs you about press information of a certain topic by your choice at a choosen time. Please enter your email address to receive the email with the press releases.

An error occurred!

Thank you! You will receive a confirmation email within a few minutes.


I want to subscribe to the gratis press mail and have read and accepted the conditions.